Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
What potential drug-drug interactions does Emgality®▼ (galcanezumab) have?
Drug interaction studies were not conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab.
As a humanised IgG4 monoclonal antibody, galcanezumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1
As such, it is not expected to
inhibit metabolic or induce enzymatic pathways
be metabolized by the cytochrome P450 families of drug-metabolizing enzymes, and
produce any active metabolites.2-4
Drug Interactions Studies Were Not Conducted
No drug interaction studies were conducted. No pharmacokinetic drug interactions are expected based on the characteristics of galcanezumab.1
There are no known interactions for galcanezumab, drug-drug or otherwise.2
3. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004;93(11):2645-2668. https://doi.org/10.1002/jps.20178
4. Kielbasa W, Helton DL. A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. Cephalalgia. 2019;39(10):1284-1297. http://dx.doi.org/10.1177/0333102419840780
IgG = immunoglobulin G
IgG4 = immunoglobulin G (subclass) 4
PK = pharmacokinetics
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: June 10, 2019